Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John L P Thompson

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|October 30, 2004
ALS issues in clinical trials. Missing dataJohn L P Thompson, Gilberto Levy
The New England Journal of Medicine|January 17, 2003
Warfarin, aspirin, or both after myocardial infarctionPatrick Pullicino, John L P Thompson
Stroke|November 3, 2016
Response by Di Tullio et al to Letter Regarding Article, "Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial"Marco R Di Tullio, John L P Thompson, Shunichi Homma, et al.
Neurology. Genetics|March 31, 2018
Diagnostic odyssey of patients with mitochondrial disease: Results of a surveyJohnston Grier, Michio Hirano, Amel Karaa, et al.
Clinical Trials (London, England)|July 9, 2011
Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III designBruce Levin, John L P Thompson, Bibhas Chakraborty, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|November 20, 2009
Web-based data management for a phase II clinical trial in ALSRichard Buchsbaum, Petra Kaufmann, Alexandra I Barsdorf, et al.
Journal of Cardiac Failure|February 28, 2006
Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and designPatrick Pullicino, John L P Thompson, Bruce Barton, et al.
Molecular Genetics and Metabolism|July 23, 2016
Mitochondrial disease patients' perception of dietary supplements' useAmel Karaa, Joshua Kriger, Johnston Grier, et al.
The American Journal of Medicine|August 23, 2023
Machine Learning Predicting Atrial Fibrillation as an Adverse Event in the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) TrialYing Gue, Elon Correa, John L P Thompson, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 5, 2013
Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patientsRonit Reich-Slotky, Jinsy Andrews, Bin Cheng, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders : Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases|October 30, 2004
ALS issues in clinical trials. Missing dataJohn L P Thompson, Gilberto Levy
The New England Journal of Medicine|January 17, 2003
Warfarin, aspirin, or both after myocardial infarctionPatrick Pullicino, John L P Thompson
Stroke|November 3, 2016
Response by Di Tullio et al to Letter Regarding Article, "Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial"Marco R Di Tullio, John L P Thompson, Shunichi Homma, et al.
Neurology. Genetics|March 31, 2018
Diagnostic odyssey of patients with mitochondrial disease: Results of a surveyJohnston Grier, Michio Hirano, Amel Karaa, et al.
Clinical Trials (London, England)|July 9, 2011
Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III designBruce Levin, John L P Thompson, Bibhas Chakraborty, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases|November 20, 2009
Web-based data management for a phase II clinical trial in ALSRichard Buchsbaum, Petra Kaufmann, Alexandra I Barsdorf, et al.
Journal of Cardiac Failure|February 28, 2006
Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and designPatrick Pullicino, John L P Thompson, Bruce Barton, et al.
Molecular Genetics and Metabolism|July 23, 2016
Mitochondrial disease patients' perception of dietary supplements' useAmel Karaa, Joshua Kriger, Johnston Grier, et al.
The American Journal of Medicine|August 23, 2023
Machine Learning Predicting Atrial Fibrillation as an Adverse Event in the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) TrialYing Gue, Elon Correa, John L P Thompson, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 5, 2013
Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patientsRonit Reich-Slotky, Jinsy Andrews, Bin Cheng, et al.
Pageof 6